Aspire Biopharma Holdings (ASBP) Share-based Compensation (2025 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Share-based Compensation came in at $157500.0 in Q2 2026, down 100.0% quarter-over-quarter from $13.4 billion in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Share-based Compensation (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Share-based Compensation for 2 consecutive years, with $157500.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Share-based Compensation changed N/A year-over-year to $157500.0 in Q2 2026; TTM through Jun 2026 was $13.4 billion, a 94768.87% increase from a year earlier, with the FY2025 full-year figure at $14.1 million, changed N/A from the prior year.
- Share-based Compensation was $157500.0 for Q2 2026 at Aspire Biopharma Holdings, down from $13.4 billion in the prior quarter.
- Over five years, Share-based Compensation peaked at $13.4 billion in Q1 2026 and troughed at $157500.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 120.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | 157,500.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 157,500.00 |
| Mar 31, 2026 | 13.41 Bn |
| Mar 31, 2025 | 14.13 Mn |